BiotechTube

Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Esophageal Squamous Cell Carcinoma

Conditions

Esophageal Squamous Cell Carcinoma

Trial Timeline

Mar 27, 2025 → Nov 1, 2029

NCT ID
NCT06644781

About Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)

Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl) is a phase 3 stage product being developed by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06644781. Target conditions include Esophageal Squamous Cell Carcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06644781Phase 3Recruiting

Competing Products

20 competing products in Esophageal Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Ramucirumab + Paclitaxel + PlaceboEli LillyPhase 3
77
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
41
Ramucirumab + Paclitaxel + Sacituzumab Tirumotecan + Rescue Medications + HER3-DXdDaiichi SankyoPhase 1/2
41
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
zolbetuximabAstellas PharmaPre-clinical
23
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPre-clinical
23
epirubicin + oxaliplatin + capecitabine + zolbetuximabAstellas PharmaPhase 2
52
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
77
zolbetuximabAstellas PharmaPhase 1
33
FamotidineAstellas PharmaPhase 2/3
65
ASP546CAstellas PharmaPhase 1/2
41
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
77
Gentuximab + PaclitaxelSun PharmaceuticalPhase 1/2
41
JS001 + nab-paclitaxel + Cisplatin + CarboplatinSun PharmaceuticalPhase 2
52
E3810 + E3810 + PlaceboEisaiPhase 3
77
Rabeprazole ER + RanitidineEisaiPhase 3
77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85